Hostname: page-component-586b7cd67f-r5fsc Total loading time: 0 Render date: 2024-11-27T04:45:58.645Z Has data issue: false hasContentIssue false
  • English
  • Français

Individually Titrated High-dose Baclofen for the Treatment of Alcohol Dependence (baclad Study) – a Randomized Controlled Trial

Published online by Cambridge University Press:  15 April 2020

C.A. Müller ,
O. Geisel ,
P. Pelz ,
V. Higl ,
J. Krüger ,
A. Stickel ,
A. Beck ,
K.D. Wernecke ,
R. Hellweg  and
A. Heinz
C.A. Müller
Affiliation:
Department of Psychiatry and Psychotherapy CCM, Charité, Berlin, Germany
O. Geisel
Affiliation:
Department of Psychiatry and Psychotherapy CCM, Charité, Berlin, Germany
P. Pelz
Affiliation:
Department of Psychiatry and Psychotherapy CCM, Charité, Berlin, Germany
V. Higl
Affiliation:
Department of Psychiatry and Psychotherapy CCM, Charité, Berlin, Germany
J. Krüger
Affiliation:
Department of Psychiatry and Psychotherapy CCM, Charité, Berlin, Germany
A. Stickel
Affiliation:
Department of Psychiatry and Psychotherapy CCM, Charité, Berlin, Germany
A. Beck
Affiliation:
Department of Psychiatry and Psychotherapy CCM, Charité, Berlin, Germany
K.D. Wernecke
Affiliation:
CCM, Charité, Berlin, Germany
R. Hellweg
Affiliation:
Department of Psychiatry and Psychotherapy CCM, Charité, Berlin, Germany
A. Heinz
Affiliation:
Department of Psychiatry and Psychotherapy CCM, Charité, Berlin, Germany

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Preclinical and first clinical studies suggested that the selective γ-aminobutyric acid (GABA)-B receptor agonist baclofen might be effective in the treatment of alcohol dependence. However, previous randomized controlled trials have reported inconsistent results, possibly related to the low to medium dosages of baclofen used in these studies.

Objectives

To assess the efficacy and safety of individually titrated high-dose baclofen (30-270 mg/d) for the treatment of alcohol dependence.

Methods

Fifty-six alcohol-dependent patients were randomized to a double-blind treatment with individually titrated baclofen or placebo. Multiple primary outcome measures were total abstinence and cumulative abstinence duration during a 12-week high-dose phase.

Preliminary results of this clinical trial will be presented.

Type
Article: 1611
Information
European Psychiatry , Volume 30 , Issue S1: Abstracts of the 23rd European Congress of Psychiatry , March 2015 , pp. 1
Copyright
Copyright © European Psychiatric Association 2015
Submit a response

Comments

No Comments have been published for this article.